Real world study to assessing the clinical effectiveness of first-line ipilimumab and nivolumab (IPI-NIVO) and second line (2L) therapy in metastatic renal cell carcinoma (mRCC) patients
Latest Information Update: 01 Apr 2022
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary) ; Cabozantinib (Primary) ; Ipilimumab (Primary) ; Lenvatinib (Primary) ; Nivolumab (Primary) ; Pazopanib (Primary) ; Pembrolizumab (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 19 Feb 2022 Results assessing all patients who received second-line cabozantinib, were presented at the 2022 Genitourinary Cancers Symposium.
- 19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium
- 20 Jul 2021 New trial record